Okumura

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--A new special report published in the American Journal of Obstetrics and Gynecology (AJOG) provides a groundbreaking approach to preeclampsia, one of the most pressing issues in maternal health today and will translate the prediction of risk into prevention of disease. The report, “Care plan for individuals at risk for preeclampsia: Shared approach to education, strategies for prevention, surveillance and follow up,” provides specific recommendations for both expecting parents and clinicians. The Care Plan’s recommendations include consideration of daily low-dose aspirin, surveillance, behavioral strategies, patient and provider education, addressing social determinants of health, and long-term follow up. These recommendations are a significant shift from the current care approach, which has historically lacked a comprehensive, integrated strategy. While technology to reliably predict preeclampsia is imminent, until now there has not been clear direction on optimal strategies for its prevention. A leading cause of pregnancy-related deaths in the U.S.,1 preeclampsia is a disorder of high blood pressure that can result in preterm birth, organ damage, and other severe complications during pregnancy. The impact of preeclampsia can extend across a lifetime for both moms and babies. With maternal mortality rising in recent years2 and high blood pressure disorders in pregnancy (including preeclampsia) doubling since 20073, there is an urgent need to predict, prevent, and mitigate its devastating impact. Fortunately, there are several effective interventions that have been associated with reduced risk of preeclampsia in individuals at increased risk.4-6 The new AJOG report synthesizes them all into an objective, evidence-based recommendation for the first time and provides checklists for both individuals at risk and health care providers, which can be downloaded and shared. Today, most pregnant individuals at increased risk do not receive even one of the interventions to prevent preeclampsia. For example, less than half of high-risk patients receive low-dose aspirin.7 By streamlining the evidence-based recommendations into a straightforward Care Plan, the report systematically outlines the multi-pronged preventive approach that patients at risk should be receiving, which includes: Key recommendations for health care providers: Risk assessment including social determinants of health, pharmacological recommendations (including aspirin therapy and antihypertensive therapy), and behavioral recommendations (including specific information about diet, exercise, and sleep) Key recommendations for persons at-risk for preeclampsia: To discuss with a health care provider: Questions regarding aspirin use, exercise during pregnancy, blood pressure monitoring, and more To do on their own: Watching for signs of preeclampsia with symptoms listed, checking blood pressure at home and reporting any readings greater than 140/90, implementing dietary, exercise, and sleep changes, and more To discuss with a health care provider: Questions regarding aspirin use, exercise during pregnancy, blood pressure monitoring, and more To do on their own: Watching for signs of preeclampsia with symptoms listed, checking blood pressure at home and reporting any readings greater than 140/90, implementing dietary, exercise, and sleep changes, and more “This new comprehensive Care Plan, developed by a diverse group of preeclampsia experts, payers and advocates is a specific and clear set of recommendations based on peer-reviewed evidence and expert opinion,” said James Roberts, M.D., a Maternal-Fetal Medicine researcher at the Magee-Womens Research Institute, UPMC and founding Principal Investigator of the Global Pregnancy Collaboration who is one of the lead authors. “The plan outlines medications, monitoring, behavioral modification, education, and considerations for social determinants of health. It is designed to be as safe, cost-effective, and practical to implement in real world practice as possible. The clear checklists further encourage their use for any pregnancy considered to be at increased risk for developing preeclampsia,” added Dr. Roberts. He said the team intends to have these checklists translated into multiple languages to further improve access and use. ”Objective prediction of preeclampsia risk months in advance will soon be possible, and the Care Plan answers the question of what to do with that information,’” said Alison Cowan, M.D., M.S.C.R. and Head of Medical Affairs at Mirvie. “An unprecedented collaboration between medical experts and preeclampsia advocates created this novel patient-centered Care Plan. It represents a critical step in preventing preeclampsia and saving lives.” Mirvie, a company developing the first platform to predict pregnancy complications by revealing the underlying biology, supported the independent development of this report to contribute to an increased understanding of how to prevent preeclampsia. Eleni Tsigas, CEO of the Preeclampsia Foundation and one of the co-authors, noted, “By centering preeclampsia survivors as experts and co-authors, alongside clinicians, researchers, and payers, we have produced a practical and proactive comprehensive Care Plan. It is written in clear and simple language, can be easily incorporated into electronic health record (EHR) systems, and is designed to be a cooperative plan for both women and their care teams. With consistent implementation in any setting, we expect this Care Plan will help address inequalities in maternal care.” With objective, predictive testing for preeclampsia imminently on the horizon, this integrated Care Plan will translate risk prediction into disease prevention. As many women without traditional risk factors will still develop preeclampsia, this combination of novel predictive and preventive tools will prove to be indispensable for all clinicians and patients seeking to prevent this serious pregnancy complication and the lifelong health impacts of preeclampsia. About Mirvie Mirvie is shaping the future of pregnancy health by providing women, expecting parents and their doctors with an early detection window to intervene before unexpected pregnancy complications become a crisis. One in five pregnancies is impacted by complications that lead to lifelong health consequences for expecting parents and babies. The proprietary Mirvie RNA platform uses a simple blood test to reveal vital information about a pregnancy’s unique biology and detect complications months before they occur. The idea for Mirvie was sparked by the personal experience of one of the founders whose daughter was born prematurely. Mirvie’s team of world-class scientists and entrepreneurs have brought to market category-first, non-invasive tests in both women’s health and in early cancer detection, used by millions today. Founded in 2018, Mirvie has raised more than $90 million in early-stage financing from top-tier investors, including Decheng Capital, Foresite Capital, General Catalyst, GV, Khosla Ventures, and Mayfield. Mirvie is based in South San Francisco, California. To learn more about Mirvie, please visit www.mirvie.com. About Global Pregnancy Collaboration The Global Pregnancy Collaboration (CoLab) is an international consortium of 40 centers. CoLab promotes collaboration in pregnancy research to improve maternal and child health worldwide. This is accomplished by assisting collaboration and sharing of data and biological samples, and education with special attention to developing research infrastructure in low-resource settings. Efforts address the needs of all maternal child health care—from the simplest in the most resource-poor countries to the most sophisticated research in more privileged areas. For more information, visit https://pregnancycolab.tghn.org. About Preeclampsia Foundation The Preeclampsia Foundation is a U.S.-based 501(c)(3) non-profit organization established in 2000 to improve the outcomes of hypertensive disorders of pregnancy by educating, supporting, and engaging the community, improving healthcare practices, and finding a cure. We envision a world where preeclampsia and related hypertensive disorders of pregnancy no longer threaten the lives of mothers and babies. For more information, visit www.preeclampsia.org. References» Mehr auf businesswire.com

LAS VEGAS--(BUSINESS WIRE)--SciPlay Corporation (NASDAQ: SCPL) (the “Company”) announced today it will release its financial results for the first quarter 2023, ended March 31, 2023, on Tuesday, May 9, 2023, after market close. The Company will host an investor audio conference call and simultaneous webcast on Wednesday, May 10, 2023, at 8:30 a.m. Eastern Time to discuss the financial results. We encourage participants to pre-register for the audio conference call or webcast by using the following link. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to the call start time. To pre-register, click here: SciPlay Investor Call Investor Conference Call May 10, 2023 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time Telephone Dial-in Telephone Replay US Toll Free: +1 (833) 630-1073 A telephone replay of the call will be available for two weeks. International Toll: +1 (412) 317-1833 US Toll Free: +1 (877) 344-7529 Conference ID: SciPlay Call International Toll: +1 (412) 317-0088 Replay Access Code: 7231695 Investor Webcast To access the live conference call or webcast, please visit the Company’s Investor News and Events section of its website https://investors.sciplay.com/news-and-events/events-and-presentations and click on the webcast link. A replay of the webcast will be available approximately one hour after the webcast and will be archived on the Company’s website. About SciPlay SciPlay Corporation (NASDAQ: SCPL) is a leading developer and publisher of digital games on mobile and web platforms. SciPlay currently offers social casino games Jackpot Party® Casino, Gold Fish® Casino, Quick Hit® Slots, 88 Fortunes® Slots, MONOPOLY Slots, and Hot Shot Casino®, and casual games Bingo Showdown®, Solitaire Pets™ Adventure, and Backgammon Live and a variety of hyper casual games such as Rob Master 3d™, Deep Clean Inc.™ and Oh God™. All of SciPlay’s games are offered and played on multiple platforms, including Apple, Google, Facebook, and Amazon. In addition to developing original games, SciPlay has access to a library of more than 1,500 real-world slot and table games provided by Light & Wonder, and its Subsidiaries. For more information, please visit SciPlay.com. All ® and © notices signify copyrights owned by and/or marks registered in the United States by SciPlay Games, LLC or LNW Gaming, Inc., and or their respective affiliates. ©2023 SciPlay Corporation. All Rights Reserved.» Mehr auf businesswire.com

MENLO PARK, Calif.--(BUSINESS WIRE)--Synthekine Inc., an engineered cytokine therapeutics company, today announced that two poster presentations showcasing its next series of oncology programs will be delivered at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023 taking place in Orlando, FL from April 14-19, 2023. "We are excited to present on two programs from our maturing oncology pipeline at AACR 2023,” said Debanjan Ray, chief executive officer of Synthekine. “We are introducing the clinical trial design for our orthogonal IL-2 and CD19 CAR-T combination therapy, STK-009 + SYNCAR-001. This unique combination pioneers new ground in the field of cytokine supported cell therapy, and is our second oncology program to enter clinical studies, behind STK-012, our alpha/beta-biased IL-2 partial agonist.” Ray continued, “We are also introducing STK-026, our IL-12 partial agonist program, which is currently in IND-enabling studies and shows promise as a potent immunotherapy for the treatment of cancer. Systemically administered wild-type IL-12 has been shown to cause significant toxicity. Our approach with STK-026 leverages Synthekine’s expertise in structural biology, immunology, and protein engineering to bias IL-12 activity and expand the therapeutic index.” Details are as follows and available on the AACR online itinerary planner: Title: Trial in Progress: A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001) and Orthogonal IL-2 (STK-009) in Subjects With Relapsed or Refractory CD19+ Hematologic Malignancies (NCT05665062) Session Title: Phase I Clinical Trials in Progress Session Date & Time: Monday Apr 17, 2023 1:30 PM - 5:00 PM ET Location: Poster Section 46 Poster Board Number: 13 Abstract Number: CT125 Summary: A first-in-human, open-label, dose escalation study of combination SYNCAR-001 + STK-009 in adults with relapsed or refractory (r/r) CD19+ hematologic malignancies (NCT05665062). The objectives of this study are to evaluate the safety, preliminary efficacy, pharmacokinetics, immunogenicity, and pharmacodynamics of SYNCAR-001 + STK-009. Recruitment in the Phase 1 study is underway. Title: Novel IL-12 Partial Agonist For Cancer Immunotherapy Avoids NK-cell Mediated Toxicity Session Title: Immunomodulatory Agents and Interventions 2 Session Date & Time: Monday Apr 17, 2023 9:00 AM - 12:30 PM ET Location: Poster Section 24 Poster Board Number: 5 Abstract Number: 1833 Summary: A novel human IL-12 partial agonist (STK-026) has been designed to more selectively engage antigen activated T-cells and to reduce stimulation of NK cells. In preclinical models, a mouse surrogate of STK-026 retained anti-tumor efficacy without induction of severe toxicities and spike in NK cell activation associated with wild-type mouse IL-12 treatment. Similarly, STK-026 avoided NK hyperactivation on human cells. These data suggest IL-12 partial agonists may represent a novel immunotherapy approach to maintain efficacy while avoiding classical toxicity associated with IL-12 therapy. Copies of the posters will be available on Synthekine’s website following presentation at the meeting. About Synthekine Synthekine is harnessing the potential of cytokine therapeutics to develop selective immunotherapies designed to improve the treatment paradigm of cancer and inflammatory disease. Using insights on cytokine structure and function, the company engineers therapeutics designed to unlock the full efficacy potential of cytokines while avoiding their associated toxicities. Synthekine is applying principles of cytokine partial agonism and immunological specificity across multiple protein engineering platforms to create a broad and deep pipeline of product candidates. These novel immunotherapies include modified cytokines, cytokine-enhanced cell therapies and surrogate cytokine agonists. For more information, visit www.www.synthekine.com, and follow us on Twitter @synthekine and LinkedIn.» Mehr auf businesswire.com